抗 CD137 和 PD-1/PD-L1 抗体走向临床协同作用。
Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
机构信息
Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
出版信息
Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.
Abstract
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models. Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. .
摘要
T 细胞共刺激和共抑制可分别通过阻断和激动性 mAb 来利用。这两种策略可以在小鼠模型中协同结合。抗 PD-1 mAb 与激动性抗 CD137（4-1BB）mAb 联合使用的早期临床结果显示出极好的安全性和有前途的疗效。
Zotero 插件